This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SINNECKER, G. Articles by KÖHLER, S. Search for Related Content PubMed PubMed Citation Articles by SINNECKER, G. Articles by KÖHLER, S.

Sex Hormone-Binding Globulin Response to the Anabolic Steroid Stanozolol: Evidence for Its Suitability as a Biological Androgen Sensitivity Test^*

GERNOT SINNECKER and SIGRUN KÖHLER

Department of Pediatrics, University of Hamburg Hamburg, West Germany

Address all correspondence and requests for reprints to: Dr. G. Sinnecker, Department of Pediatrics, University of Hamburg Eppendorf, Martinistrasse 52, 2000 Hamburg 20, West Germany.

Both the androgen-induced decline in serum sex hormone-binding globulin (SHBG) levels during puberty and the anabolic effect of exogenous testosterone are absent in patients with androgen insensitivity (testicular feminization). To determine whether the androgen-induced decline in serum SHBG could be used as a test of androgen sensitivity, we studied the effect of the anabolic-androgenic steroid stanozolol (17β-hydroxy-17-methyl-5-androstano-[3,2-c]pyrazol) on serum SHBG in 25 control subjects, 3 patients with complete androgen insensitivity, and 4 patients with partial androgen insensitivity. Stanozolol was administered orally for 3 days (0.2 mg/kg·day); blood samples were taken before and 5, 6, 7, and 8 days after the beginning of the test for measurements of serum SHBG. The lowest value (i.e. the peak response) in each subject was used as the measure of the response to stanozolol. In the control subjects the mean nadir serum SHBG level was 51.6 ± 5.9% (±SD) of the initial value (P < 0.001). In the 4 patients with partial androgen insensitivity the nadir serum SHBG ranged from 73–89%, and in the 3 patients with complete androgen insensitivity it ranged from 93–97% of the initial value. Thus, the decrease in serum SHBG after short term administration of stanozolol reflects androgen responsiveness and, thus, may be used to differentiate patients with androgen insensitivity syndromes from those with other causes of male pseudohermaphroditism.

^* This work was supported by the German Research Foundation (DFG Grant Si 323/2-1).

Part of a thesis by S.K.

Received October 27, 1988.

This article has been cited by other articles:

				R. Werner, P.-M. Holterhus, G. Binder, H.-P. Schwarz, M. Morlot, D. Struve, C. Marschke, and O. Hiort The A645D Mutation in the Hinge Region of the Human Androgen Receptor (AR) Gene Modulates AR Activity, Depending on the Context of the Polymorphic Glutamine and Glycine Repeats J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3515 - 3520. [Abstract] [Full Text] [PDF]

				A. W. F. T. Toorians, S. Kelleher, L. J. Gooren, M. Jimenez, and D. J. Handelsman Estimating the Contribution of the Prostate to Blood Dihydrotestosterone J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5207 - 5211. [Abstract] [Full Text] [PDF]

				T. Raivio, J. S. Tapanainen, P. Kunelius, and O. A. Janne Serum Androgen Bioactivity During 5{alpha}-Dihydrotestosterone Treatment in Elderly Men J Androl, November 1, 2002; 23(6): 919 - 921. [Abstract] [Full Text] [PDF]

				P.-M. Holterhus, G. H. G. Sinnecker, and O. Hiort Phenotypic Diversity and Testosterone-Induced Normalization of Mutant L712F Androgen Receptor Function in a Kindred with Androgen Insensitivity J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3245 - 3250. [Abstract] [Full Text]